Abstract
Objectives
The purpose of this study was to evaluate an association found between overall survival of patients with pharyngeal squamous cell carcinoma (SCC) and pretreatment [18F]-2-fluorodeoxyglucose (18F-FDG) uptake, which are assessed by positron emission tomography combined with computed tomography (PET/CT). Next, we asked whether 18F-FDG uptake is correlated with overall survival in patients with pharyngeal SCC who underwent radical treatments such as surgery and radiotherapy in the multivariate analysis with adjustments for the clinical stage, primary site and treatment group.
Methods
Forty-nine patients who were newly diagnosed as resectable pharyngeal SCC underwent pretreatment 18F-FDG-PET/CT. We used the maximum standardized uptake value (SUVmax) as 18F-FDG uptake. Overall survival rate was calculated by the Kaplan–Meier method. Univariate survival analysis was analyzed by log-rank test, and multivariate survival analysis was performed by a Cox proportional hazards model.
Results
Patients with SUVmax of the primary site ≥8 significantly exhibited shorter overall survival in univariate analysis (p < 0.04). Moreover, SUVmax of the primary site ≥8 was a significant prognostic factor in the multivariate analysis (p < 0.03).
Conclusions
These results suggested that SUVmax of the primary site obtained by pretreatment 18F-FDG-PET/CT assessment is an important prognostic factor in patients with pharyngeal SCC.
Similar content being viewed by others
References
Barnes L, Eveson JW, Reichart P, Sidransky D. World Health Organization classification of tumours. Pathology and genetics of head and neck tumours. Lyon: IARC Press; 2005.
Schwartz DL, Rajendran J, Yueh B, Coltrera MD, Leblanc M, Eary J, et al. FDG-PET prediction of head and neck squamous cell cancer outcomes. Arch Otolaryngol Head Neck Surg. 2004;130(12):1361–7.
van Baardwijk A, Dooms C, van Suylen RJ, Verbeken E, Hochstenbag M, Dehing-Oberije C, et al. The maximum uptake of 18F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1α and GLUT-1 in non-small cell lung cancer. Eur J Cancer. 2007;43(9):1392–8.
Suzuki H, Kato K, Fujimoto Y, Itoh Y, Hiramatsu M, Maruo T, et al. 18F-FDG-PET/CT predicts survival in hypopharyngeal squamous cell carcinoma. Ann Nucl Med. 2013;27:297–302.
Xie P, Li M, Zhao H, Sun X, Fu Z, Yu J. 18F-FDG PET or PET–CT to evaluate prognosis for head and neck cancer: a meta-analysis. J Cancer Res Clin Oncol. 2011;137:1085–93.
Zhang B, Li X, Lu X. Standardized uptake value is of prognostic value for outcome in head and neck squamous cell carcinoma. Acta Otolaryngol. 2010;130:756–62.
Lin SC, Liao CY, Kao CH, Yen KY, Yang SN, Wang YC, et al. Pretreatment maximal standardized uptake value of primary tumor predicts outcome to radiotherapy in patients with pharyngeal cancer. J Radiat Res. 2012;53(3):462–8.
Kim SY, Roh JL, Kim MR, Kim JS, Choi SH, Nam SY, et al. Use of 18F-FDG PET for primary treatment strategy in patients with squamous cell carcinoma of the oropharynx. J Nucl Med. 2007;48:752–7.
Inokuchi H, Kodaira T, Tachibana H, Nakamura T, Tomita N, Nakahara R, et al. Clinical usefulness of [18F] fluoro-2-deoxy-d-glucose uptake in 178 head-and-neck cancer of patients with nodal metastasis treated with definitive chemoradiotherapy: consideration of its prognostic value and ability to provide guidance for optimal selection of patients for planned neck dissection. Int J Radiat Oncol Biol Phys. 2011;79(3):747–55.
Howard JD, Lu B, Chung CH. Therapeutic targets in head and neck squamous cell carcinoma: identification, evaluation, and clinical translation. Oral Oncol. 2012;48(1):10–7.
Suzuki H, Hasegawa Y, Terada A, Hyodo I, Nakashima T, Nishio M, et al. FDG–PET predicts survival and distant metastasis in oral squamous cell carcinoma. Oral Oncol. 2009;45(7):569–73.
Suzuki H, Fukuyama R, Hasegawa Y, Tamaki T, Nishio M, Nakashima T, et al. Tumor thickness, depth of invasion, and Bcl-2 expression are correlated with FDG-uptake in oral squamous cell carcinomas. Oral Oncol. 2009;45:891–7.
Suzuki K, Nishioka T, Homma A, Tsuchiya K, Yasuda M, Aoyama H, et al. Value of fluorodeoxyglucose positron emission tomography before radiotherapy for head and neck cancer: does the standardized uptake value predict treatment outcome? Jpn J Radiol. 2009;27(6):237–42.
Palma P, Conde-Muino R, Rodriguez-Fernandez A, Segura-Jimenez I, Sanchez-Sanchez R, Martin-Cano J, et al. The value of metabolic imaging to predict tumour response after chemoradiation in locally advanced rectal cancer. Radiat Oncol. 2010;5:119.
Funk GF. A head and neck surgeon’s perspective on best practices for the use of PET/CT scans for the diagnosis and treatment of head and neck cancers. Arch Otolaryngol Head Neck Surg. 2012;138(8):748–52.
Ishizuka M, Fujimoto Y, Itoh Y, Kitagawa K, Sano M, Miyagawa Y, et al. Relationship between hematotoxicity and serum albumin level in the treatment of head and neck cancers with concurrent chemoradiotherapy using cisplatin. Jpn J Clin Oncol. 2011;41(8):973–9.
Acknowledgments
This study was supported by JSPS KAKENHI Grant Number 24791821.
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Suzuki, H., Kato, K., Fujimoto, Y. et al. Prognostic value of 18F-fluorodeoxyglucose uptake before treatment for pharyngeal cancer. Ann Nucl Med 28, 356–362 (2014). https://doi.org/10.1007/s12149-014-0817-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12149-014-0817-x